| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The primary target of SGK1-IN-4 is serum- and glucocorticoid-regulated kinase 1 (SGK1), a serine/threonine protein kinase that plays a critical role in cell survival, proliferation, and ion transport. SGK1-IN-4 is a selective inhibitor of SGK1. By inhibiting SGK1, the compound may modulate various physiological processes, including inflammation, apoptosis, and electrolyte balance.
|
|---|---|
| ln Vitro |
In vitro, SGK1-IN-4 inhibits human SGK1 with an IC50 of 3 nM at an ATP concentration of 500 µM. The compound is a potent and selective inhibitor of SGK1. It can be used to study the role of SGK1 in various cellular processes, including cell survival, proliferation, and ion transport.
|
| ln Vivo |
In vivo, SGK1-IN-4 is orally bioactive. It may have potential therapeutic applications in osteoarthritis and other diseases where SGK1 plays a role. However, detailed in vivo studies on its efficacy and safety are limited.
|
| Enzyme Assay |
The in vitro enzyme assay for SGK1-IN-4 involves measuring the inhibition of SGK1 kinase activity. SGK1 is incubated with its substrate and ATP in the presence of the compound. The phosphorylation of the substrate is measured using a radioactive or luminescent assay. The IC50 value is calculated by fitting dose-response curves to the inhibition data.
|
| Cell Assay |
Cellular assays for SGK1-IN-4 typically involve the use of cell lines that express SGK1. Cells are treated with the compound, and the phosphorylation of SGK1 substrates, such as NDRG1, is measured using Western blotting or ELISA. The compound's effects on cell proliferation, survival, and signaling pathways may also be assessed.
|
| Animal Protocol |
In vivo animal studies for SGK1-IN-4 would typically involve oral administration of the compound to rodent models of osteoarthritis or other diseases. Following treatment, disease progression, inflammation, and tissue damage are assessed. The compound's ability to inhibit SGK1 and modulate disease-related endpoints is evaluated. However, specific in vivo study protocols for this compound are not detailed in the available literature.
|
| ADME/Pharmacokinetics |
As a small molecule, the pharmacokinetic properties of SGK1-IN-4 would depend on its physicochemical characteristics. The compound is orally bioactive, suggesting good oral bioavailability. It has a molecular weight of 517.96 g/mol. Detailed ADME parameters such as half-life, bioavailability, and tissue distribution are not available in the public domain.
|
| Toxicity/Toxicokinetics |
There is no specific toxicity data reported for SGK1-IN-4 in the available literature. As a research chemical, the compound is intended for laboratory use only and should be handled with standard safety precautions. Toxicity studies would be required if the compound were to be developed further for therapeutic applications.
|
| References | |
| Additional Infomation |
SGK1-IN-4 (CAS#: 1628048-93-0) is a selective inhibitor of serum- and glucocorticoid-regulated kinase 1 (SGK1). It is a selective, orally bioactive SGK1 inhibitor. The compound has a molecular formula of C23H21ClFN5O4S and a molecular weight of 517.96. SGK1-IN-4 can be used in studies about osteoarthritis. It has an IC50 of 3 nM against human SGK1.
|
| Molecular Formula |
C23H21CLFN5O4S
|
|---|---|
| Molecular Weight |
517.96
|
| Exact Mass |
517.098
|
| CAS # |
1628048-93-0
|
| PubChem CID |
90421307
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
35
|
| Complexity |
806
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(S(NC2=CC=C(C3=NC(O[C@@H]4CC[C@@H](O)CC4)=C4C=NNC4=N3)C=C2)(=O)=O)=CC(Cl)=CC=C1F
|
| InChi Key |
IKBMUGXVSJZWGW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H21ClFN5O4S/c24-14-3-10-19(25)20(11-14)35(32,33)30-15-4-1-13(2-5-15)21-27-22-18(12-26-29-22)23(28-21)34-17-8-6-16(31)7-9-17/h1-5,10-12,16-17,30-31H,6-9H2,(H,26,27,28,29)
|
| Chemical Name |
5-chloro-2-fluoro-N-[4-[4-(4-hydroxycyclohexyl)oxy-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (482.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.02 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (4.02 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.02 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9307 mL | 9.6533 mL | 19.3065 mL | |
| 5 mM | 0.3861 mL | 1.9307 mL | 3.8613 mL | |
| 10 mM | 0.1931 mL | 0.9653 mL | 1.9307 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
